Ipamorelin
Selective growth hormone secretagogue (GHRP) with minimal effect on cortisol or prolactin.
FEMETRIC · 21+ ONLYFEMETRIC is a research and educational platform intended only for adults age 21 and older.
Acceptance is stored on this device and requested again after approximately 30 days.Search peptides, goals, protocols and references
EXPLORE THIS GOAL · PB
Endurance, recovery and lean-mass research. Use this dashboard to move between records, protocols, comparisons, research and tools.
Selective growth hormone secretagogue (GHRP) with minimal effect on cortisol or prolactin.
Long-acting GHRH analog that provides sustained GH and IGF-1 elevation for several days.
Short-acting GHRH analog that amplifies the body’s natural growth-hormone pulses.
Synthetic 15-amino-acid gastric peptide researched for tissue repair, gut protection, and anti-inflammatory effects.
GLP-1 / GIP / Glucagon triple agonist for substantial weight loss and metabolic improvement.
Mitochondrial-derived peptide that activates AMPK and supports metabolic flexibility, insulin sensitivity, and exercise capacity.
Dual GIP / GLP-1 receptor agonist for superior weight loss and glycemic control.
Long-acting selective GLP-1 receptor agonist for weight loss and glycemic control.
Long-acting amylin analog for appetite regulation and weight management (often studied with semaglutide as CagriSema).
Fixed dual combination of long-acting amylin analog + GLP-1 agonist for enhanced weight loss.
Synthetic GHRH analog that stimulates endogenous GH release for visceral fat reduction.
Modified hGH fragment (176-191) studied for lipolysis without significant IGF-1 elevation.
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Synthetic fragment of Thymosin Beta-4 that promotes cell migration and systemic tissue repair.
BUILD FROM THIS RESEARCH CONTEXT
The goal stays visible in the stack builder. Related records are suggestions by tag overlap; you choose what to add.